<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769116</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-9001-102</org_study_id>
    <nct_id>NCT03769116</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer&#xD;
      in DMD patients by measuring biological and clinical endpoints in three parts: two 48-week&#xD;
      randomized, double-blinded, placebo-controlled periods (Part 1 and Part 2), and an open-label&#xD;
      follow-up period (Part 3). Patients who are randomized to placebo in Part 1 will have the&#xD;
      opportunity for treatment with SRP-9001 in Part 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2018</start_date>
  <completion_date type="Anticipated">April 2, 2026</completion_date>
  <primary_completion_date type="Actual">December 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel up to the measurement of the primary outcome at Week 48. At the beginning of Part 2, patients who were originally assigned to placebo will have the opportunity to receive SRP-9001. All patients will be followed for 5 years following treatment with SRP-9001.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Quantity of Micro-dystrophin Protein Expression as Measured by Western Blot</measure>
    <time_frame>Baseline up to Week 12 (Part 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score</measure>
    <time_frame>Baseline up to Week 48 (Part 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Rise From the Floor</measure>
    <time_frame>Baseline up to Week 48 (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time to Ascend 4 Steps</measure>
    <time_frame>Baseline up to Week 48 (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time of 10 Meter Timed Test</measure>
    <time_frame>Baseline up to Week 48 (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time of 100 Meter Timed Test</measure>
    <time_frame>Baseline up to Week 48 (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of Micro-dystrophin Expression Measured by Immunofluorescence (IF) Fiber Intensity</measure>
    <time_frame>Baseline up to Week 12 (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of Micro-dystrophin Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)</measure>
    <time_frame>Baseline up to Week 12 (Part 1)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs) and Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Week 260</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>SRP-9001 in Part 1 Followed by Placebo in Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive SRP-9001 at Part 1 followed by matching Placebo at Part 2 followed by an open-label extension at Part 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Part 1 Followed by SRP-9001 in Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive matching Placebo at Part 1 followed by SRP-9001 at Part 2 followed by an open-label extension at Part 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SRP-9001</intervention_name>
    <description>Single IV infusion of SRP-9001</description>
    <arm_group_label>Placebo in Part 1 Followed by SRP-9001 in Part 2</arm_group_label>
    <arm_group_label>SRP-9001 in Part 1 Followed by Placebo in Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusion of matching placebo</description>
    <arm_group_label>Placebo in Part 1 Followed by SRP-9001 in Part 2</arm_group_label>
    <arm_group_label>SRP-9001 in Part 1 Followed by Placebo in Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD&#xD;
             phenotype.&#xD;
&#xD;
          -  Indication of symptomatic muscular dystrophy by protocol-specified criteria.&#xD;
&#xD;
          -  Ability to cooperate with motor assessment testing.&#xD;
&#xD;
          -  Stable dose equivalent of oral corticosteroids for at least 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiovascular function on ECHO.&#xD;
&#xD;
          -  Prior or ongoing medical condition on physical examination, ECG, or laboratory&#xD;
             findings that could adversely affect subject safety, compromise completion of&#xD;
             follow-up, or impair assessment of study results.&#xD;
&#xD;
          -  Exposure to another investigational drug or exon skipping medication within 6 months&#xD;
             of screening.&#xD;
&#xD;
          -  Exposure to an investigational or commercial gene therapy product.&#xD;
&#xD;
          -  Abnormal liver or renal function by protocol-specified criteria&#xD;
&#xD;
        Other inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Gene-Delivery</keyword>
  <keyword>DMD</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <keyword>North Star Ambulatory Assessment (NSAA)</keyword>
  <keyword>Percent Dystrophin Positive Fibers (PDPF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

